Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.31 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28400172 | 0.83 | — | — | |
| SCHEMBL29184811 | 0.82 | KDM4E (0.33) | — | |
| SCHEMBL10884873 | 0.82 | TSHR (0.32) | TSHRGABRA5GABRB2GABRA1GABRR1 | |
| SCHEMBL2793941 | 0.80 | KDM4E (0.30) | — | |
| SCHEMBL28735814 | 0.79 | SLC6A3 (0.36) | TSHRLMNA | |
| SCHEMBL11119178 | 0.79 | — | — | |
| SCHEMBL28735789 | 0.77 | SLC6A2 (0.39) | — | |
| SCHEMBL3986419 | 0.76 | CPN1 (0.39) | CPN1CPB2TSHRSLC6A1SLC6A11 | |
| SCHEMBL21831618 | 0.75 | — | — | |
| SCHEMBL219820 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117222646-A | KRAS G12C inhibitors and uses thereof | 苏州赞荣医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-7579368-B2 | Cis-imidazolines | HOFFMAN-LA ROCHE INC. (US) | 2009-08-25 | — | — | US | disclosed |
| CN-101155784-A | Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | disclosed |
| EP-1861376-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F. Hoffmann-Roche AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211693-A1 | Cis-imidazolines | FOTOUHI NADER | 2006-09-21 | — | — | US | disclosed |
| CN-1078968-A | 2-Piperazinone compounds and their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-12-01 | — | — | CN | disclosed |
| CN-1069730-A | 2-Piperazinone compounds and their preparation and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-03-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211693-A1 | Cis-imidazolines | TP53, MDM2, CDC25C | CPN1 2870/4885CPB2 2274/4885TSHR 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.